Empowering Clinical Development Teams with our Innovative AI
Optimize Trial Design and Late Phase Decision-Making by Uncovering Actionable Insights From Your Trial Data.
Optimize Trial Design with NetraMark
Discover Optimal Dosage
Understand Your Treatment’s Ideal Subpopulations
Increase Effect Size
Identify Causal Variables of Patient Response
Minimize Adverse Events
Detect Drivers of Meaningful Clinical Benefit
A Next Generation AI Solution Revolutionizing Clinical Trials
Unlock the potential of your clinical trials through a novel AI solution.
Effortlessly generate and decipher insights on treatment efficacy, toxicity, and placebo response
Know Your Patients
NetraAI is built to uncover the hidden relationship between patients in your clinical trial by using novel methods and empowering scientists to make critical decisions.
NetraAI, powered by Attractor AI, a proprietary long-range attractor algorithm, deciphers hidden patient correlations in your clinical trials, providing optimal causal factors with exceptional clarity and explainability.
Know Your Disease
Unlock the factors behind the heterogeneity of your patient population with our technology. Use these high dimensional views to enhance enrichment, reducing clinical trial risks and fostering success. Avoid populations that can hinder your development early on.
Design Smarter Patient-Centric Protocols With Intelligence
NetraAI generates insights that drastically improve inclusion/exclusion criteria leading to larger effect sizes and lower p values. Find the maximum population that is likely to be responsive and make phase III studies smaller and more efficient.
Publications, White Papers & Posters
Small Patient Datasets Reveal Genetic Drivers of Non-Small Cell Lung Cancer Subtypes using a Novel Machine For Hypothesis Generation
July 26, 2023 | Moses Cook, Bessi Qorri, Amruth Baskar, Jalal Ziauddin, Luca Pani, Shashi Bushan Yenkanchi, Joseph Geraci
Using Artificial Intelligence-based Methods to Address the Placebo Response in Clinical Trials
January – March 2022 | Erica A. Smith, William P. Horan, Dominique Demolle, Peter Schueler, Dong-Jing Fu, Ariana E. Anderson, Joseph Geraci, Florence Butlen-Ducuing, Jasmine Link, Ni A. Khin, Robert Morlock, & Larry D. Alphs
Using machine intelligence to uncover Alzheimer’s disease progression heterogeneity
December, 31 2020 | Bessi Qorri, Mike Tsay, Abhishek Agrawal, Rhoda Au, & Joseph Geraci
Disrupting the Aging Process
Jan 2019 | Stephan Boissonneault
Next-Gen AI for Disease Definition, Patient Stratification, and Placebo Effect
21 July 2020 | Mike Tsay, Joseph Geraci, Abhishek Agrawal
Evaluation of postmortem microarray data in bipolar disorder using traditional data comparison and artificial intelligence reveals novel gene targets
October 2021 | Jaehyoung Choi, David F. Bodenstein, Joseph Geraci, & Ana C. Andreazza
Shattering cancer with quantum machine learning: A preview
11 Jun 2021| Joseph Geraci
Quantum and classical machine learning for the classification of non-small-cell lung cancer patients
16 May 2020 | Siddhant Jain, Jalal Ziauddin, Paul Leonchyk, Shashibushan Yenkanchi & Joseph Geraci
Attractor AI Provides Machine Learning Algorithms With The Power Of Causal Inference Through An Innovative Look-Back Memory Technology
Meet The Founder
Dr Joseph Geraci, Ph.D. is a mathematician, medical scientist, and quantum machine learning specialist. He holds postdocs in artificial intelligence, oncology, and neuropsychiatry. He has developed novel machine intelligence algorithms that are capable of providing extraordinary insights into small complex data sets, like those found in clinical trials.
He is associated with the department of Molecular Medicine and Pathology at Queen’s University in Ontario, Canada and the Centre for Biotechnology and Genomics Medicine Medical College of Georgia, USA, and is a visiting scientist in quantum computation and neuroscience at the University of California, San Diego.